Performance indicators
Deliver high-value medicines performance indicators
|
2022 |
2021 |
2020 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projects entering development pipeline 2 |
5 |
7 |
6 |
||||||||||||
Ongoing Phase III programs 3 |
44 |
54 |
44 |
||||||||||||
US FDA breakthrough therapy designations 4 |
1 |
3 |
2 |
||||||||||||
Major submissions (US, EU, JP, China) 5 |
24 |
34 |
13 |
||||||||||||
Major approvals (US, EU, JP, China) 5 |
23 |
21 |
26 |
||||||||||||
New molecular entity (NME) approvals 6 |
1 |
2 |
4 |
||||||||||||
|
Patient health and safety performance indicators
|
2022 |
2021 |
2020 |
||||
---|---|---|---|---|---|---|---|
GxP audits |
|
|
|
||||
Total audits executed |
1 392 |
1 419 |
903 |
||||
Internal 1 |
134 |
125 |
111 |
||||
External 2 |
1 258 |
1 294 |
792 |
||||
Regulatory authorities |
|
|
|
||||
Total inspections |
139 |
126 |
126 |
||||
Inspections found to be acceptable (%) |
100 |
99.2 |
99.2 |
||||
US FDA |
|
|
|
||||
FDA inspections |
10 |
10 |
6 |
||||
FDA warning letters |
0 |
0 |
0 |
||||
FDA Form 483 |
7 |
5 |
1 |
||||
US FDA sponsor inspections |
|
|
|
||||
Inspections related to clinical trial management and pharmacovigilance |
1 |
3 |
1 |
||||
Number of FDA VAI (voluntary action indicated) classifications |
0 |
0 |
0 |
||||
Number of FDA OAI (official action indicated) classifications |
0 |
0 |
0 |
||||
Recalls |
|
|
|
||||
Total recalls |
19 |
27 |
27 |
||||
Class I recalls |
0 |
3 |
1 |
||||
Class II recalls |
16 |
20 |
21 |
||||
US FDA |
|
|
|
||||
FDA recalls |
1 |
1 |
0 |
||||
|
Supply chain performance indicators
|
2022 |
2021 |
2020 |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Suppliers risk-assessed by Third-Party Risk Management (TPRM) 1 |
|
|
|
||||||||||
Number of suppliers risk-assessed by TPRM |
11 097 |
12 064 |
8 448 |
||||||||||
Suppliers assessed by risk area 2 |
|
|
|
||||||||||
Anti-bribery |
1 553 |
2 303 |
2 014 |
||||||||||
Animal welfare 3 |
18 |
9 |
10 |
||||||||||
Health, safety and environment |
296 |
477 |
315 |
||||||||||
Information security and data privacy |
6 694 |
5 668 |
3 174 |
||||||||||
Labor rights |
5 379 |
6 755 |
4 635 |
||||||||||
Quality GmP 4 |
594 |
848 |
561 |
||||||||||
Actions taken |
|
|
|
||||||||||
Suppliers audited |
86 |
85 |
35 |
||||||||||
Suppliers with remediation action agreed 5 |
384 |
912 |
521 |
||||||||||
Supplier engagements stopped due to risk assessment outcomes |
17 |
37 |
120 |
||||||||||
|
Environment performance indicators
|
2022 |
2021 |
2020 |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Energy use - on site and purchased (million GJ) |
9.9 |
9.8 |
10.9 |
||||||||||||||||||
Greenhouse gas (GHG) emissions (1 000 tCO2e) |
|
|
|
||||||||||||||||||
Total Scope 1 emissions |
347.2 |
352.8 |
378.3 |
||||||||||||||||||
Combustion and process |
256.4 |
264.1 |
287.0 |
||||||||||||||||||
Vehicles |
90.8 |
88.7 |
91.3 |
||||||||||||||||||
Total Scope 2 emissions (market based) |
154.9 |
292.7 |
335.5 |
||||||||||||||||||
Total Scope 2 emissions (location based) 2 |
399.2 |
439.4 |
487.2 |
||||||||||||||||||
Total Scope 1 and Scope 2 (excluding offsets) |
502.1 |
645.5 |
713.8 |
||||||||||||||||||
Total Scope 3 emissions 3 |
8 770.0 |
7 290.4 |
7 268.8 |
||||||||||||||||||
Purchased goods and services |
7 350.6 |
5 958.4 |
5 754.0 |
||||||||||||||||||
Capital goods |
301.2 |
303.8 |
278.7 |
||||||||||||||||||
Business travel 4 |
93.0 |
36.2 |
68.3 |
||||||||||||||||||
Use of sold products 5 |
260.1 |
199.2 |
163.9 |
||||||||||||||||||
Total Scope 1, Scope 2 and Scope 3 emissions |
9 272.1 |
7 935.9 |
7 982.6 |
||||||||||||||||||
Carbon offsets 6 |
30.7 |
–34.7 |
33.6 |
||||||||||||||||||
GHG emissions intensity (tCO2e) |
|
|
|
||||||||||||||||||
Scope 1 and Scope 2 per million USD sales |
9.9 |
12.3 |
14.4 |
||||||||||||||||||
Scope 1 and Scope 2 per FTE |
4.9 |
6.1 |
6.6 |
||||||||||||||||||
VOCs (t) |
|
|
|
||||||||||||||||||
Halogenated volatile organic compounds |
0.8 |
0.8 |
11.6 |
||||||||||||||||||
Non-halogenated volatile organic compounds |
313.1 |
304.7 |
443.0 |
||||||||||||||||||
Water (million m3) |
|
|
|
||||||||||||||||||
Total water withdrawal 7 |
52.1 |
47.6 |
54.7 |
||||||||||||||||||
Surface water |
7.9 |
6.5 |
7.1 |
||||||||||||||||||
Groundwater |
36.8 |
35.3 |
41.7 |
||||||||||||||||||
Third-party water |
7.4 |
5.8 |
5.9 |
||||||||||||||||||
Total water discharged 8 |
49.6 |
46.6 |
54.5 |
||||||||||||||||||
Water consumption 9 |
7.5 |
7.7 |
8.4 |
||||||||||||||||||
Operational waste (1 000 t) |
|
|
|
||||||||||||||||||
Total waste generated |
97.0 |
103.6 |
130.6 |
||||||||||||||||||
Total non-hazardous waste |
63.6 |
66.7 |
68.7 |
||||||||||||||||||
Total hazardous waste |
33.4 |
36.9 |
61.9 |
||||||||||||||||||
Total waste diverted from disposal |
69.5 |
73.4 |
88.6 |
||||||||||||||||||
Non-hazardous waste recycled |
53.4 |
56.0 |
59.9 |
||||||||||||||||||
Hazardous waste recycled |
16.1 |
17.4 |
28.7 |
||||||||||||||||||
Total waste directed to disposal |
27.5 |
30.2 |
42.1 |
||||||||||||||||||
Non-hazardous waste not recycled |
10.2 |
10.7 |
8.8 |
||||||||||||||||||
Hazardous waste not recycled |
17.3 |
19.5 |
33.3 |
||||||||||||||||||
|
People performance indicators
|
2022 |
2021 |
2020 |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Headcount 1 |
105 533 |
108 514 |
110 738 |
||||||||||||||||||
Full-time equivalent positions 1 |
101 703 |
104 323 |
105 794 |
||||||||||||||||||
Percentage turnover: voluntary / overall |
9 / 15 |
8 / 13 |
5 / 10 |
||||||||||||||||||
Percentage of hires: internal / external |
66 / 34 |
62 / 38 |
58 / 42 |
||||||||||||||||||
Annual learning hours per employee 2 |
42.4 |
52.1 |
53.2 |
||||||||||||||||||
Representation of nationalities: overall / management 3 |
147 / 118 |
143 / 115 |
142 / 113 |
||||||||||||||||||
Employees represented by an employee representative body or covered by a collective bargaining agreement (%) 4 |
48 |
47 |
46 |
||||||||||||||||||
Health and safety |
|
|
|
||||||||||||||||||
Lost-time injury and illness rate (per 200 000 hours worked): |
0.16 / 0.20 |
0.14 / 0.05 |
0.12 / 0.20 |
||||||||||||||||||
Total recordable case rate (per 200 000 hours worked) 5: |
0.31 / 0.28 |
0.25 / 0.13 |
0.23 / 0.30 |
||||||||||||||||||
Fatalities: Novartis employees / Third-party personnel / Contractors |
0 / 0 / 0 |
0 / 0 / 0 |
0 / 0 / 1 |
||||||||||||||||||
Gender representation (% female / % male) 6 |
|
|
|
||||||||||||||||||
Overall headcount |
51 / 49 |
51 / 49 |
50 / 50 |
||||||||||||||||||
Hires |
52 / 48 |
52 / 47 |
52 / 48 |
||||||||||||||||||
Promotions |
53 / 47 |
55 / 45 |
52 / 48 |
||||||||||||||||||
Overall turnover |
49 / 51 |
50 / 50 |
49 / 51 |
||||||||||||||||||
Voluntary turnover |
51 / 49 |
51 / 49 |
52 / 48 |
||||||||||||||||||
Board of Directors |
31 / 69 |
31 / 69 |
29 / 71 |
||||||||||||||||||
Executive Committee of Novartis |
27 / 73 |
25 / 75 |
23 / 77 |
||||||||||||||||||
Novartis Top Leaders 7 |
39 / 61 |
38 / 62 |
33 / 67 |
||||||||||||||||||
Senior management |
41 / 59 |
39 / 61 |
39 / 61 |
||||||||||||||||||
Middle management |
48 / 52 |
47 / 53 |
46 / 54 |
||||||||||||||||||
Overall management 3 |
47 / 53 |
46 / 54 |
45 / 55 |
||||||||||||||||||
Entry-level positions |
52 / 48 |
52 / 48 |
52 / 48 |
||||||||||||||||||
Revenue-producing roles 8 |
51 / 49 |
51 / 49 |
50 / 50 |
||||||||||||||||||
STEM roles 9 |
46 / 54 |
46 / 54 |
46 / 54 |
||||||||||||||||||
Gender representation by contract type (female / male) |
|
|
|
||||||||||||||||||
Permanent |
52 311 / 49 549 |
53 509 / 51 497 |
53 729 / 53 096 |
||||||||||||||||||
Temporary |
1 881 / 1 709 |
1 854 / 1 539 |
1 935 / 1 629 |
||||||||||||||||||
Full time |
47 631 / 50 084 |
48 618 / 51 904 |
48 472 / 53 507 |
||||||||||||||||||
Part-time |
6 573 / 1 175 |
6 755 / 1 133 |
7 204 / 1 219 |
||||||||||||||||||
Number of employees by region, by contract type (permanent / temporary) |
|
|
|
||||||||||||||||||
Asia-Pacific |
27 197 / 486 |
28 229 / 420 |
27 711 / 300 |
||||||||||||||||||
Europe, Middle East and Africa |
54 892 / 2 943 |
55 362 / 2 752 |
56 852 / 3 016 |
||||||||||||||||||
Latin America |
4 508 / 92 |
5 101 / 127 |
5 092 / 157 |
||||||||||||||||||
North America |
15 263 / 69 |
16 314 / 94 |
17 170 / 91 |
||||||||||||||||||
|
Access to healthcare performance indicators
|
2022 |
2021 |
2020 |
||
---|---|---|---|---|---|
Overall patients reached (millions) |
|
|
|
||
Patients reached through access approaches 1 |
54.6 |
56.2 |
66.4 |
||
Sustainability-linked bond (September 23, 2020 – September 23, 2028) |
|
|
|
||
Patients reached with strategic innovative therapies |
1 197 352 |
947 699 |
695 669 |
||
Patients reached through flagship programs |
31 157 087 |
32 695 224 |
43 912 152 |
||
|
Health system strengthening performance indicators
|
2022 |
2021 |
2020 |
||||
---|---|---|---|---|---|---|---|
Health educators trained |
4 477 |
2 827 |
671 |
||||
Healthcare providers trained |
12 035 |
10 719 |
12 648 |
||||
Points of service provision 2 |
1 313 |
4 365 |
5 902 |
||||
People reached at points of service provision |
979 755 |
360 356 |
486 642 |
||||
Awareness events held |
297 700 |
412 872 |
424 878 |
||||
People reached at awareness events |
12 960 922 |
9 678 360 |
8 048 360 |
||||
|
Animals needed for research
|
2022 |
2021 |
2020 |
||
---|---|---|---|---|---|
Total |
332 668 |
353 772 |
410 359 |
||
Rodents |
261 256 |
265 111 |
312 332 |
||
% of total |
78.5 |
74.9 |
76.1 |
||
Zebrafish |
70 826 |
88 229 |
97 596 |
||
% of total |
21.3 |
24.9 |
23.8 |
||
Other species |
586 |
432 |
431 |
||
% of total |
0.2 |
0.1 |
0.1 |
||
|
Ethical business practices performance indicators
|
2022 |
2021 |
2020 |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Code of Ethics |
|
|
|
||||||||||
Employees trained and certified (%) 1 |
98 |
98 |
98 |
||||||||||
Grievance indicators: SpeakUp Office - central matters 2, 3 |
|
|
|
||||||||||
Misconduct cases reported |
385 |
174 |
157 |
||||||||||
Total allegations 4 |
544 |
296 |
284 |
||||||||||
Allegations substantiated 5 |
257 |
137 |
118 |
||||||||||
Total allegations substantiated per category (%): SpeakUp Office - central matters |
|
|
|
||||||||||
Fraud/asset misappropriation |
7 |
13 |
7 |
||||||||||
Expense fraud |
2 |
4 |
2 |
||||||||||
Books and records, accounting irregularities |
0 |
0 |
1 |
||||||||||
Improper professional practices |
12 |
20 |
14 |
||||||||||
Bribery, kickbacks |
0 |
2 |
1 |
||||||||||
Discrimination and sexual harassment |
3 |
8 |
11 |
||||||||||
Retaliation |
1 |
5 |
3 |
||||||||||
Other employee relations issues |
5 |
14 |
18 |
||||||||||
Conflict of interest |
5 |
12 |
13 |
||||||||||
IT security breach |
41 |
4 |
4 |
||||||||||
Quality assurance / data integrity |
2 |
3 |
8 |
||||||||||
Data privacy |
12 |
3 |
2 |
||||||||||
Antitrust, fair competition |
0 |
1 |
1 |
||||||||||
Company confidential / trade secret information |
1 |
2 |
4 |
||||||||||
Other |
9 |
9 |
11 |
||||||||||
Dismissals and resignations related to misconduct |
116 |
62 |
101 |
||||||||||
|
Download all performance indicators here |
|
42 kB |